Alexandria Hammond's Stock Ratings

B of A Securities Analyst

Alexandria Hammond is an analyst at B of A Securities. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 04/16/2025

Overall Average Return

-9.95%

Smart Score

37.2%

Overall Average Return Percentile

24th

Number of Ratings

14
Buy NowGet Alert
01/30/2025AKROBuy Now
Akero Therapeutics
$38.0865.44%
Alexandria Hammond37%
$35 → $63UpgradeNeutral → BuyGet Alert
11/15/2024REGNBuy Now
Regeneron Pharmaceuticals
$556.00106.83%
Alexandria Hammond37%
→ $1150Initiates → OutperformGet Alert
11/15/2024PFEBuy Now
Pfizer
$22.5211.01%
Alexandria Hammond37%
→ $25Initiates → UnderperformGet Alert
11/15/2024MRNABuy Now
Moderna
$25.6056.25%
Alexandria Hammond37%
→ $40Initiates → UnderperformGet Alert
11/15/2024MRKBuy Now
Merck & Co
$78.25—
Alexandria Hammond37%
—Initiates → Peer PerformGet Alert
11/15/2024LLYBuy Now
Eli Lilly
$759.0031.75%
Alexandria Hammond37%
→ $1000Initiates → OutperformGet Alert
11/15/2024JNJBuy Now
Johnson & Johnson
$153.7523.58%
Alexandria Hammond37%
→ $190Initiates → OutperformGet Alert
11/15/2024GILDBuy Now
Gilead Sciences
$105.993.78%
Alexandria Hammond37%
→ $110Initiates → OutperformGet Alert
11/15/2024BMYBuy Now
Bristol-Myers Squibb
$49.90—
Alexandria Hammond37%
—Initiates → Peer PerformGet Alert
11/15/2024BIIBBuy Now
Biogen
$116.98—
Alexandria Hammond37%
—Initiates → Peer PerformGet Alert
11/15/2024ABBVBuy Now
AbbVie
$175.9216.53%
Alexandria Hammond37%
→ $205Initiates → OutperformGet Alert
04/22/2024AKROBuy Now
Akero Therapeutics
$38.08-21.22%
Alexandria Hammond37%
→ $30Reinstates → NeutralGet Alert
04/22/2024MDGLBuy Now
Madrigal Pharmaceuticals
$321.10-53.29%
Alexandria Hammond37%
→ $150Initiates → UnderperformGet Alert
04/22/2024ETNBBuy Now
89bio
$6.05395.87%
Alexandria Hammond37%
→ $30Assumes → BuyGet Alert